Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, P° Castellana 261, 2804, Madrid, Spain.
Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, P° Castellana 261, 2804, Madrid, Spain.
Injury. 2020 Apr;51 Suppl 1:S63-S73. doi: 10.1016/j.injury.2020.02.070. Epub 2020 Feb 26.
Advanced therapy medicinal products (ATMP) frequently lack of clinical data on efficacy to substantiate a future clinical use. This study aims to evaluate the efficacy to heal long bone delayed unions and non-unions, as secondary objective of the EudraCT 2011-005441-13 clinical trial, through clinical and radiological bone consolidation at 3, 6 and 12 months of follow-up, with subgroup analysis of affected bone, gender, tobacco use, and time since the original fracture.
Twenty-eight patients were recruited and surgically treated with autologous bone marrow derived mesenchymal stromal cells expanded under Good Manufacturing Practices, combined to bioceramics in the surgical room before implantation. Mean age was 39 ± 13 years, 57% were males, and mean Body Mass Index 27 ± 7. Thirteen (46%) were active smokers. There were 11 femoral, 4 humeral, and 13 tibial non-unions. Initial fracture occurred at a mean ± SD of 27.9 ± 31.2 months before recruitment. Efficacy results were expressed by clinical consolidation (no or mild pain if values under 30 in VAS scale), and by radiological consolidation with a REBORNE score over 11/16 points (value of or above 0.6875). Means were statistically compared and mixed models for repeated measurements estimated the mean and confidence intervals (95%) of the REBORNE Bone Healing scale. Clinical and radiological consolidation were analyzed in the subgroups with Spearman correlation tests (adjusted by Bonferroni).
Clinical consolidation was earlier confirmed, while radiological consolidation at 3 months was 25.0% (7/28 cases), at 6 months 67.8% (19/28 cases), and at 12 months, 92.8% (26/28 cases including the drop-out extrapolation of two failures). Bone biopsies confirmed bone formation surrounding the bioceramic granules. All locations showed similar consolidation, although this was delayed in tibial non-unions. No significant gender difference was found in 12-month consolidation (95% confidence). Higher consolidation scale values were seen in non-smoking patients at 6 (p = 0.012, t-test) and 12 months (p = 0.011, t-test). Longer time elapsed after the initial fracture did not preclude the occurrence of consolidation.
Bone consolidation was efficaciously obtained with the studied expanded hBM-MSCs combined to biomaterials, by clinical and radiological evaluation, and confirmed by bone biopsies, with lower consolidation scores in smokers.
高级治疗药物产品(ATMP)通常缺乏疗效临床数据来证实未来的临床应用。本研究旨在通过临床和影像学骨愈合评估在 3、6 和 12 个月随访时治疗长骨延迟愈合和不愈合的疗效,亚组分析受累骨、性别、吸烟和原始骨折后时间的疗效。
28 名患者被招募并接受了自体骨髓来源间充质基质细胞(MSC)的手术治疗,这些细胞是在符合良好生产规范的条件下扩增的,并在植入前的手术室内与生物陶瓷结合使用。平均年龄为 39±13 岁,57%为男性,平均体重指数为 27±7。13 名(46%)为主动吸烟者。有 11 例股骨、4 例肱骨和 13 例胫骨不愈合。最初的骨折发生在招募前的平均±SD 27.9±31.2 个月。疗效结果通过临床愈合(VAS 量表中值低于 30 为无或轻度疼痛)和 REBORNE 评分超过 11/16 分(值等于或高于 0.6875)的影像学愈合来表示。平均值进行了统计学比较,并使用重复测量混合模型估计了 REBORNE 骨愈合量表的平均值和置信区间(95%)。使用 Spearman 相关检验对临床和影像学亚组进行分析(通过 Bonferroni 调整)。
临床愈合更早得到证实,而 3 个月时的影像学愈合率为 25.0%(28 例中的 7 例),6 个月时为 67.8%(28 例中的 19 例),12 个月时为 92.8%(28 例中的 26 例,包括 2 例失败的外推)。骨活检证实了生物陶瓷颗粒周围的骨形成。所有部位的愈合情况相似,尽管胫骨不愈合的愈合时间较长。在 12 个月的随访中,没有发现性别差异(95%置信区间)。非吸烟者在 6 个月(p=0.012,t 检验)和 12 个月(p=0.011,t 检验)时的愈合评分更高。原始骨折后时间的延长并没有排除愈合的发生。
通过临床和影像学评估,以及骨活检证实,用研究中扩增的 hBM-MSC 联合生物材料治疗,可有效地获得骨愈合,吸烟者的愈合评分较低。